Our Story

Now recognised as the largest and most established multi-stakeholder rare disease meeting, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape.

With 700+ potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the political, commercial and scientific issues in manufacturing, clinical trials, strategy, regulation & policy, Market Access & Pricing, Science & Strategy, Pitch & Partner and Precision Medicine.







Pricing and access to medicines is a very challenging and complex journey, and even more so when we consider new, innovative gene therapies and rare orphan drugs. That’s why the WODC has dedicated 4 days of content on addressing these issues. This includes value evidence and perspectives from industry and patients, feedback from HTAs and payers on commercial negotiations to large European initiatives and health ministers to gain better insights on its sustainability.


The regulatory authorities and European Commission couldn’t stress enough the importance of early dialogue and common assessment. Come to this congress to gain scientific advice, a pathway to help secure accelerated approval and early consultation. Get feedback to ensure there’s alignment between regulators, HTA and drug developers.


The rare disease community is crying out for new models to run natural history studies, registries, European Reference Networks, sustainable real-world evidence, meaningful clinical endpoints to name a few, are you inclusive in your strategy? The WODC is unique in the way we bring together all stakeholders, including patients to help challenge new partnerships and collaborations.




With the recent landmark EU approvals for one-time gene therapies, it’s imperative that as an industry we discuss and find solutions persisting questions around appropriate reimbursement models, patient access and scale up challenges.


How will the impact of new digital and computational tools affect rare disease diagnostics and patient care? Learn how genomics, sequencing and AI are changing the way patients access diagnostics and treatments. As we get all these precision medicine tools on our fingertips, treatments should become more and more accessible, find out how.

The Advisory Board


We’re proud to work alongside a stellar line up of Orphan Drug and Gene Therapy Professionals who have helped us curate the most up to date and relevant program for you.


Event growth

In the last 2 years:

We’ve been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together. Discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business.

Our world leading events bring scale, knowledge, and gravitas to promote innovation and technology that change people’s lives. Whether it is solar and renewables in Africa, education technology in Australia, payments and e-commerce in Asia, railways in the Middle East, orphan drugs in the Americas, or aviation in Europe, our events make a difference. We are creative, organic, and customer focused, curating content for the specific industry and location of each event. Whether you’re looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change.



World Orphan Drug Congress


The World Orphan Drug Congress provides you with a one stop progressive scientific and strategic solution to the orphan drugs industry.



Contact us

To sponsor or exhibit contact:
Marc Rhys-Evans


To speak:
Wing-Yun Cheung